Ketonal 50 mg capsules, hard България - български - Изпълнителна агенция по лекарствата

ketonal 50 mg capsules, hard

lek pharmaceuticals d.d.. - Кетопрофен - 50 mg capsules, hard

Ketonal Intensive 50 mg granules for oral solution in sachets България - български - Изпълнителна агенция по лекарствата

ketonal intensive 50 mg granules for oral solution in sachets

50 mg granules for oral solution in sachets

Ketonal 100 mg/2 ml solution for injection България - български - Изпълнителна агенция по лекарствата

ketonal 100 mg/2 ml solution for injection

lek pharmaceuticals d.d. - Кетопрофен - 100 mg/2 ml solution for injection

Ketonal 25 mg granules for oral solution in sachets България - български - Изпълнителна агенция по лекарствата

ketonal 25 mg granules for oral solution in sachets

25 mg granules for oral solution in sachets

Ketozal 2% shampoo България - български - Изпълнителна агенция по лекарствата

ketozal 2% shampoo

Химакс Фарма ЕООД - Кетоконазол - 2% shampoo

KETOSOL -100, 100 mg/ml solution for injection for cattle, pigs and horses 100.00 mg/ml България - български - БАБХ (Българска агенция по безопасност на храните)

ketosol -100, 100 mg/ml solution for injection for cattle, pigs and horses 100.00 mg/ml

interchemie werken de adelaar eesti as - Кетопрофен - инжекционен разтвор - 100.00 mg/ml - говеда, коне, свине

KOPHANIOS DETOXAL България - български - Ecolab

kophanios detoxal

ecolab deutschland gmbh -

Ranivisio Европейски съюз - български - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ранимизумаб - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Офталмологични - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Yesafili Европейски съюз - български - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - Офталмологични - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Koselugo Европейски съюз - български - EMA (European Medicines Agency)

koselugo

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Антинеопластични средства - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.